A new round of investment will allow Dragonfly to further accelerate development of its novel innate immune system and Natural Killer cell-based immunotherapies into the clinic.
WALTHAM, Mass., March 19, 2020 /CNW/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company") today announced that Fidelity Management & Research Company ("Fidelity") has led a new round of investment in Dragonfly, along with other major investors. This brings total equity funding plus partnership capital in the Company to over $300 million thus far, with potential future milestones of over $10 billion plus ongoing royalties.
"This investment round strengthens Dragonfly's capacity to advance our internal pipeline of drug candidates deep into the clinic," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. "We are delighted that investors see our transition to a clinical-stage company last year as a strong foundation from which to advance a series of our internal drugs for patients, even as we expand our work making drug candidates for our Pharma Collaborators."
About Dragonfly Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough disease treatments to patients.